Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...

Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...

SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui ...

SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as ...

Meanwhile his former colleague Moncef Slaoui, who also left GSK this year, has joined the European life science investor, Medicxi. Slaoui was formerly chairman of pharmaceutical R&D at GSK, and ...

Abzena (Cambridge, UK), the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Moncef Slaoui, PhD, to its Board of Directors. A ...